Form 4: Rapport Therapeutics CSO Sells Shares Under Pre-Arranged Trading Plan

Rapport Therapeutics' Chief Scientific Officer, David Bredt, sold 8,500 shares of common stock for approximately $13.9955 per share as part of a pre-established Rule 10b5-1 trading plan.

Summary

• David Bredt, Chief Scientific Officer of Rapport Therapeutics, Inc. (RAPP), sold 8,500 shares of common stock.
• The transaction occurred on July 15, 2025.
• The shares were sold at a weighted average price of $13.9955, with individual sales ranging from $13.565 to $14.50.
• Following this transaction, David Bredt directly beneficially owns 435,142 shares of common stock.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale can sometimes be perceived negatively, the fact that it was conducted under a pre-established 10b5-1 plan mitigates concerns that it's based on new, negative information. It's a routine liquidity event.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating it was pre-scheduled and not based on recent non-public information.

Negatives

• An insider sale, even if pre-planned, reduces the insider's direct equity stake in the company.

Risks

• The price reported is a weighted average, and actual sale prices varied, indicating potential price volatility during the transaction period.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The sale slightly reduces the Chief Scientific Officer's direct ownership stake, which could be interpreted as a minor reduction in alignment, though mitigated by the 10b5-1 plan.

Key Dates

Recommendation

Keywords

Rapport Therapeutics, RAPP, SEC Form 4, Insider Trading, Stock Sale, David Bredt, Chief Scientific Officer, 10b5-1 Plan, Equity Transaction